Current biological hypotheses of recurrent depression (review)

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 112, Issue 11, 2012, Pages 29-40

  Mosolov, S N ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Biological markers; Gene polymorphism; Pathogenesis; Recurrent depression; Treatment

Indexed keywords

MONOAMINE; BIOGENIC AMINE; NERVE GROWTH FACTOR;

CHRONIC STRESS; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; HEREDITY; HYPOTHESIS; NERVE DEGENERATION; NEUROIMAGING; RECURRENT BRIEF DEPRESSION; REVIEW; SOCIAL DISABILITY; CIRCADIAN RHYTHM; GENETICS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; RECURRENT DISEASE;

BIOGENIC MONOAMINES; CIRCADIAN RHYTHM; COGNITION DISORDERS; DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NERVE GROWTH FACTORS; PITUITARY-ADRENAL SYSTEM; RECURRENCE; STRESS, PSYCHOLOGICAL;

EID: 84876352563     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Adell A. LU-AA.21004 a multimodal serotonergic agent for the potential treatment of depression and anxiety. IDrugs 2010; 13: 900-910.
2. Airan R.D., Meltzer L.A., Roy M. et al. High-speed imaging reveals neuro-physiological links to behavior in an animal model of depression. Science 2007; 317: 819-823.
3. Akhondzadeh S., Jafari S., Raisi F. et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26: 607-611.
4. Alex K.D., Pehek E.A. Pharmacological mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007; 11: 3: 296-320.
5. Aloyo V.J., Berg K.A., Spampinato U. et al. Current status of inverse agonism at serotonin 2° (2-HT2A) and 5-HT2C receptors. Pharmacol Ther 2009; 121: 160-173.
6. Angelucci F., Brene S., Mathe A.A. BDNFinschizophrenia, depressionand-correspondinganimalmodels. Mol Psychiatry 2005; 10: 345-352.
7. Anisman H., Merali Z., Poulter O., Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005; 11: 963-972.
8. Ansorge M.S., Zhou M., Lira A. et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004; 306: 879-881.
9. Arencibia-Albite F., Paladini C., Williams J.T. et al. Noradrenergic modulation of the hyperpolarization-activated cation current (Ih) in dopamine neurons of the ventral tegmental area. Neuroscience 2007; 149: 303-314.
10. Avissar S., Nechamkin Y., Roitman G., Schreiber G. Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression. Am J Psychiatry 1997; 154: 211-217.
11. Barbon A., Popoli M., La Via L. et al. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by anti-depressant drugs. Biol Psychiatry 2006; 59: 713-720.
12. Bauer M., Heinz A., Whybrow P.C. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry 2002; 7: 140-156.
13. Beasley C.L., Honer W.G., Bergmann K. et al. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord 2005; 7: 449-455.
14. Belmaker R.N., Agam G. Major Depressive disorder. New England Jour Med 2008; 358: 55-68.
15. Bhagwagar Z., Wylezinska M., Jezzard P. et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007; 61: 806-812.
16. Binneman B. et al. A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the tratment of major depression. Am J Psychiatry 2008; 165: 617-620.
17. Blasey C.M., Debattista C., Roe R. et al. A multisite trial os mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp Clin Trials 2009; 30: 284-288.
18. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006; 59: 1144-1150.
19. Borbely A.A. A two process model of sleep regulation. Human Neurobiology 1982; 1: 3: 195-204.
20. Brambilla P., Perez J., Barale F. et al. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003; 8: 715: 721-737.
21. Brown E.S., Varghese F.P., McEwen B.S. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry 2004; 55: 1-9.
22. Bunney W.E., Bunney B.G. Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology 2000; 22: 335-345.
23. Burke H.M., Davis M.C., Otte C., Mohr D.C. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology 2005; 30: 846-856.
24. Candy M., Jones L., Williams R. et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; 2: D006722.
25. Capuron L., Neurauter G., Musselman D.L. et al. Interferon-alpha-induced changes in tryptophan metabolism, relationship to depression and paroxetine treatment. Biol Psychiatry 2003; 54: 906-914.
26. Carman J.S., Post R.M., Buswell R. et al. Negative effects of melatonin on depression. Am J Psychiatry 1976; 133: 1181-1186.
27. Carroll B.J., Cassidy F., Naftolowitz D. et al. Pathophysiology of hyper cortisolism in depression. Acta Psychiatr Scand Suppl 2007; 433: 90-103.
28. Caspi A., Sugden K., Moffitt T.E. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-389.
29. Castren E. Is mood chemistry? Nat Rev Neurosci 2005; 6: 241-246.
30. Chang P.P., Ford D.E., Mead L.A., Cooper-Patrick L., Klag M.J. In somnia in young men and subsequent depression. The JohnLkins precursors study. Am J Epidemiol 1997; 146: 105-114.
31. Chen B., Dowlatshahi D., MacQeen G.M. et al. Increased hippocampal BDNFimmunoreactivity in subjects treatment with antidepressant medication. Biol Psychiatry 2001; 50: 260-265.
32. Choudary P.V., Molnar M., Evans S.J. et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653-15658.
33. Conley R.K., Cumberbatch M.J., Mason G.S. et al. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 2002; 22: 7730-7736.
34. Cooper-Kazaz R., Apter J.T., Cohen R. et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679-688.
35. Coupland N.J., Ogilvie C.J., Hehadoren K.M. et al. Decreased prefrontal myo-inositol in major depressive disorder. Biol Psychiatry 2005; 57: 1526-1534.
36. DeBattista C., Belanoff J., Glass S. et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006; 60: 1343-1349.
37. de Pablos R.M., Villaran R.F., Argüelles S. et al. Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci 2005; 26: 5709-5719.
38. Desan P.H., Oren D.A., Malison R. et al. Genetic polimorhism at the CLOCK gene locus and major depression. Am J Med Genet 2000; 96: 418-421.
39. Desouza L.A., Ladiwala U., Daniel S.M. et al. Thyroid hormone regulates hippocampal neurogenesis in the adult rat brain. Mol Cell Neurosci 2005; 29: 414-426.
40. Dombrovski A.Y., Mulsant B.H., Houck P.R. et al. Residual symptoms and recurrence during maintenance treatment of late depression. J Affect Disord 2007; 103: 77-82.
41. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
42. Duncan W.C.J. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 1996; 71: 3: 253-312.
43. Ebner K., Sartori S.B., Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 2009; 154: 1647-1674.
44. Ehlers C.L., Frank E. Social zeitgebers and biological rhythms. Gen Psychiatry 1988; 45: 948-952.
45. El Mansari M., Chanbari R., Janssen S., Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008; 55: 1191-1198.
46. Emens J. et al. Depression and phase angle difference of melatonin production. Psychiatry Res 2009; 8: 30-36.
47. Emens J., Lewy A., Kinzie J.M. et al. Circadian misaligument in major de-pressive disoredre. Psychiatry Res 2009; 8: 30-36.
48. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the orefrontal cortex in major depression. Biol Psychiatry 2009; 33: 70-75.
49. Flores B.H., Kenna H., Keller J. et al. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006; 31: 628-636.
50. Folstein M., Liu T., Peter I. et al. The homocysteine hypothesis of depression. Am J Psychiatry 2007; 164: 861-867.
51. Ford D.J., Kamerow D.B. Epidemiological study of sleep disturbances and psychiatric disoders. Am J Med Assoc 1989; 1479-1484.
52. Foster F.G., Kupfer D.J. Psychomotor activity as a correlate of depression and sleep in acutely disturbed psychiatric inpatients. Am J Psychiatry 1975; 132: 928-931.
53. Frodl T., Schüle C., Schmitt G. et al. Association of the brain-derived neurotrophic factor Va166Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 2007; 64: 410-416.
54. Fuchs E., Schmelting B., Mocaer E. Effects of the novel antidepressant agomelatine (S 20098) and Fluoxetine in chronically stressed tree shrews, an animal model of depression. EurNeu-ropsychopharmacol 2006; 16(Suppl 4): 338-344.
55. George M.S., Belmaker R.H. (eds). Transcranial magnetic stimulation in clinical psychiatry. Washington, DC: American Psychiatry Publishing 2007.
56. Germain A., Nofzinger E.A., Meltzer C.C. et al. Diurnal variation in regional brain glucose metabolism in depression. Biol Psychiatry 2007; 62: 438-445.
57. Gershon A.A., Vishne T., Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007; 61: 145-153.
58. Goetze U., Tolle R. Circadian rhythm of free urinary cortisol, temperature and heart rate in endogenous depressives and under antidepressant therapy. Neuropsychobiology 1987; 18: 175-184.
59. Goshen I., Kreisel T., Ben-Menachem-Zidon O. et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2009; 8: 125.
60. Guiard B.P., El Mansari M., Merali Z., Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo alectrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 2008; 11: 625-639.
61. Hasler G., Neumeister A., van der Veen J.W. et al. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 2005; 58: 969-973.
62. Hasler G., van der Veen J.W., Tumonis T. et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscory. Arch Gen Psychiatry 2007; 64: 193-200.
63. Hasler G., Fromm S., Carlson P.J. et al. Neural response to cate-cholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry 2008; 65: 521-531.
64. Hastings R.S., Parsey R.V., Oquendo M.A. et al. Volumetric analysis of the prefrontal cortex, amygdale, and hippocampus in major depression. Neuropsychopharmacology 2004; 29: 952-959.
65. Hernandez M.E., Mendieta D., Martinez-Fong D. et al. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol 2008; 18: 917-924.
66. Holmans P., Weissman M.M., Zubenko G.S. et al. Genetics of recurrent early-onset major depression (GenRED): final genome scan report. Am J Psychiatry 2007; 164: 248-258.
67. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsycho-pharmacology 2000; 23: 477-501.
68. Janicki-Deverts D., Cohen S., Doyle W.J. et al. Infection-induced proinflammatory cytokines are associated with decreases in positive affect, But not increases in negative affect. Brain Behav Immun 2007; 21: 301-307.
69. Janowsky D.S., Overstreet D.H. Cholinergic-muscarinic dysfunction in mood disorders. Soares J.C., Young A.H., eds. Bipolar disorders: Basic mechanisms and therapeutic implications. 2nd ed., New York: Informa Healthcare 2007; 67-88.
70. Johansson C., Willei M., Smedh C. et al. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 2003; 28: 734-739.
71. Karege F., Vaudan G., Schwald M. et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Mol Brain Res 2005; 136: 29-37.
72. Kehne J.H. The CRF-1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007; 6: 163-182.
73. Kendler K.S., Gardner C.O., Prescott C.A. Clinical characteristics of major depression that predict risk of depression in relatives. Arch Gen Psychiatry 1999; 56: 322-327.
74. Kendler K.S., Gatz M., Gardner C.O., Pedersen N.L. A Swedish national twin study of lifetime major depression. Am J Psychiatry 2006; 163: 109-114.
75. Kennaway D.J., Moyer R.W. Serotonin 5-HT2c agonists mimic the effect of light pulses on circadian rhythms. Brain Res 1998; 806: 257-270.
76. Kennedy S.E., Koeppe R.A., Young E.A., Zubieta J.K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006; 63: 1199-1208.
77. Koolschijn P.C., van Haren N.E., Lensvelt-Mulders G.J. et al. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009; 30: 3719-3735.
78. Kozlovsky N., Matar M.A., Kaplan Z. et al. Long-term down-regulation of BDNF mRNA in rat hippocampal CA1 subregion correlates with PTSD-like behavioural stress response. Int J Neuropsychopharmacol 2007; 10: 741-758.
79. Kramer M.S. et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-392.
80. Kripke D.F., Mullaney D.J., Atkinson M. et al. Circadian rhythm disorders in manic-depressives. Biol Psychiatry 1978; 13: 335-351.
81. Kupfer D.J., Heninger G. REM-activity as a correlate of mood changes throughout the night. Arch Gen Psychiat 1972; 27: 368-373.
82. Lacoste R., Wirz-Justice A. Seasonal variation in normal subjects: an update of variables current in depression. Seasonal Affective Disorders and Phototherapy. Rosenthal and Blehar (Eds.). Guilford Press, NY 1989; 167-229.
83. Laposky A.D., Shelton J., Dugovic C., Perrino N. Turek Altered sleep regulation in leptin deficient mouse. Am J Phy Regul Integr Comp Physiol 2006; 290: 894-903.
84. Lesch K.P., Bengel D., Heils A. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1531.
85. Lesch K.P., Greenberg B.D., Higley J.D. et al. Serotonin transporter, personality, and behavior: toward a dissection of gene-gene and gene-environment interaction. J. Benjamin, R.P. Ebstein, R.H. Belmaker, eds. Molecular genetics and the human personality. Washington, DC: American Psychiatric Publishing 2002; 109-135.
86. Lesperance F., Frasure-Smith N., Koszycki D. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evalution of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-379.
87. Lewy A.J., Rough J.N., Songer J.B. et al. The phase shift hypothesis for the circadian component of winter depression. Dialogues ClinNeurosci 2007; 9: 291-299.
88. Lopez A.D., Mathers C.D., Ezzati M. et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
89. Louis C., Cohen C., Depoortere R., Griebel G. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vesopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat. Neuropsychopharmacology 2006; 31: 2180-2187.
90. Lund R. Sleep disorders and circadian rhythms - Stress, biological rhythms and psychiatric disorders. H. Westenberg (ed.). Houten; Medidact 1989; 71-73.
91. Luo A.H., Aston-Jones G. Circuit projection from suprachiasmatic nucleus to ventral tegantal area: a novel circadian output pathway. Eur J Neurosci 2009; 29: 748-760.
92. Lyons W.E., Mamounas L.A., Ricaurte G.A. et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Nat Acad Sci USA 1999; 96: 15239-15244.
93. MacQeen G.M., Campbell S., McEwen B.S. et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Nat Acad Sci USA 2003; 100: 1387-1392.
94. Magnusson A., Partonen T. The diagnosis, symptomatology, and epidemiology of seasonal affective disorder. CNS Spectr 2005; 10: 625-634.
95. Mayberg H.S., Lozano A.M., Voon V. et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651-660.
96. McEwen B.S., Chattarji S., Diamond D.M. et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010; 15: 237-249.
97. Mendlewicz J. Neuroendocrine and sleep EEG biological markers of depression. A Chronobiological disorder - Theoretical problem of modern psychiatry. Internat symposium, Moscow, May 11-12, 1982; 115-119.
98. Merali Z., Du L., Hrdina P. et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004; 24: 1478-1485.
99. Meyer J.H., Ginovart N., Boovariwala A. et al. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63: 1209-1216.
100. Meyer J.H., McNeely H.E., Sagrati S. et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 2006; 163: 1594-1602.
101. Milak M.S., Parsey R.V., Keilp J. et al. Neuroanatomic correlates of psycho-pathologic components of major depressive disorder. Arch Gen Psychiatry 2005; 62: 397-408.
102. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-741.
103. Müller N., Schwarz M.J., Dehning S. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-684.
104. Müller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 2010; 11: 31-42.
105. Nemets B., Stahl Z., Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-479.
106. Nutt D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008; 69(Suppl 1): 4-7.
107. O'Brien S.M., Scull P., Fitzgerald P. et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007; 41: 326-331.
108. Ordway G.A., Schenk J., Stockmeier C.A. et al. Elevated agonist binding to alpha-2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry 2003; 53: 315-323.
109. Papousek M. Chronobiologisheaspekte der zyklothymie. Fortsch NeurolPsychiate 1975; 43: 381-440.
110. Partonen T., Reutlein J., Alpman A. et al. Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression. Ann Med 2005; 39: 229-238.
111. Perera T.D., Coplan J.D., Lisanby S.H. et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 2007; 27: 4894-4901.
112. Pettersson M., Campbell B.M., Dounay A.B. Design synthesis and pharmacologicalevaluation ofastatine and pirrolidine derivatives as dual nor epinephrine reuptake ingibitors and 5-HT1Apartial agonists. Bioorg Med Shem Lett 2011; 21: 865-868.
113. Pezawas L., Meyer-Lindenberg A., Drabant E.M. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8: 828-834.
114. Phelps L.E., Britsche N., Moral J.R. et al. Family history of alcohol dependence and initial antidepressants response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009; 65: 181-184.
115. Pitchot W., Hansenne M., Pinto E. 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biol Psychiatry 2005; 58: 854-858.
116. Pizzagalli D.A., Oakes T.R., Fox A.S. et al. Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry 2004; 9: 325: 393-405.
117. Popik P., Kozela E., Krawczyk M. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br J Pharmacol 2003; 139: 1196-1202.
118. Preskorn S.H., Baker B., Kolluri S. et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective-N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008; 28: 631-637.
119. Prins J., Denys D.A., Westphal K.G. et al. The putative antidepsessant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol 2010; 633: 55-61.
120. Quera Salva M.A., Vanier B., Laredo J. et al. Major depressive disoder, sleep EEC and agomelanine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691-696.
121. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48: 766-777.
122. Rajkowska G., O'Dwyer G., Teleki Z. et al. GABAergic neurons immunore-active for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007; 32: 471-482.
123. Ramírez-Rodríguez G., Klempin F., Babu H. et al. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology 2009; 32: 2180-2191.
124. Rausch J.L., Johnson M.E., Kasik K.E. et al. Temperature regulation in depression: functional 5HT1A receptor adaptation differentiates antidepressant response. Neuropsychopharmacology 2006; 31: 2274-2280.
125. Rickels K., Athanasiou M., Robinson D.S. et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 326-333.
126. Riemann D., Berger M., Voderholzer U. Sleep and depression: results from psychobiological studies: an overview. Biol Psychol 2001; 57: 67-103.
127. Rizvi S.J., Kennedy S.H. The keys to improving depression outcomes. Eur Neuropsychopharmacology 2011; 21: 694-702.
128. Rosenthal N.E., Sack D.A., Wehr T.A. Seasonal variation in affective disorders. Circadian rhythms in psychiatry. T.A. Wehr, F.K. Goodwin (Eds.). Boxwood Press; Pacific Grove 1983; 185-202.
129. Roybal K., Theobold D., Graham A. et al. Mania-like behavionr induced by disruption of CLOCK. Proc Nat Acad Sci USA 2008; 104: 6406-6411.
130. Ruhe H.G., Mason N.S., Schene A.H. Mood in indirectly related to serotonin, norepinephine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007; 12: 331-359.
131. Sanacora G., Gueorguieva R., Epperson C.N. et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61: 705-713.
132. Sanacora G., Kendell S.F., Fenton L. et al. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry 2004; 161: 2132.
133. Schmidt P.J., Daly R.C., Bloch M. et al. Dehydro epiandrosterone mono therapy in midlife-onser major and minor depression. Arch Gen Psychiatry 2005; 62: 154-162.
134. Schultz H., Lung R. Sleep REM episodes are associated with circadian parameters of body temperature. A study in depressed patients and normal controls. Biol Psychiat 1983; 18: 1411-1426.
135. Seeman P., Ko F., Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 2005; 10: 877-883.
136. Shimon H., Agam G., Belmaker R.H. et al. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am J Psychiatry 1997; 154: 1148-1150.
137. Shirayama Y., Mitsushio H., Takashima M. et al. Reduction of substance P after chronic antidepressants treatment in the striatum, substantianigra and amygdala of the rat. Brain Res 1996; 739: 70-78.
138. Shytle R.D., Silver A.A., Lukas R.J. et al. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002; 7: 525-535.
139. Sitaram N., Gillin J.C., Bunney W.E. Circadian variation in the time of «switch» of a patient with 48-hour manic-depressive cycles. Biol Psychiat 1978; 13: 567-574.
140. Souetre E., Salvati E., Belugou J.-L. et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989; 28: 263-278.
141. Spalletta G., Bossu P., Ciaramella A. et al. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006; 11: 984-991.
142. Srinivasan V. et al. Melatonin in mood disorders. World J Biol Psychiatry 2006; 7: 138-151.
143. Strous R.D., Maayan R., Lapidus R. et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003; 60: 133-141.
144. Sullivan G.M., Mann J.J., Oquendo M.A., Lo E.S. et al. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry 2006; 60: 500-506.
145. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552-1562.
146. Svenningsson P., Chergui K., Rachleff I. et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311: 77-80.
147. Taylor C.B., Youngblood M.E., Catellier D. et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792-798.
148. Torregrossa M.N., Jutkiewicz E.M., Mosberg H.I. et al. Peptidic delta opioid receptor agonists produce antidepressant-like regulate BDNF mRNA expression in rats. Brain Res 2006; 1069: 172-181.
149. Trajkovska V., Kirkegaard L., Krey G. et al. Activation of glucocorticoid receptors increases 5-HT2A receptor levels. Exp Neurol 2009; 218: 83-91.
150. Tremblay L.K., Naranjo C.A. Cardenas reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 2002; 59: 409-416.
151. Turek F.W. From circadian rhythms to clock genes in depression. Int Clin Psychopharmacol 2007; 22(Suppl 2): 1-8.
152. Varcoe T.J., Kennaway D.J. Activation of 5-HT2C receptors acutely induces Perl gene expression in the rat SCN in vitro. Brain Res 2008; 1209: 19-28.
153. Valdizan E.M., Utierrez O., Pazos A. Adenylatecyclase activity in postmortem brain of suicide subjects: redused response to beta-adrenergic stimulation. Biol Psychiatry 2003; 54: 1457-1464.
154. Watanabe K., Hashimoto E., Ukai W. et al. Effect of antidepressants on brain-derived neurotrophic factor (BDNF) release from platelets in the rats. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1450-1454.
155. Weaver I.C., Cervoni N., Champagne F.A. et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004; 7: 847-854.
156. Weber M.M., Emrich H.M. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol 1988; 3: 255-266.
157. Wehr T.A. Phase and biorhythm studies of affective illness. Ann Intern Med 1977; 87: 319-333.
158. Wehr T.A., Goodwin F.K. Biological rhythms in manic-depressive illness - Circadian rhythms in psychiatry. Wehr T.A., Goodwin F.K. (Eds.). The Boxwood Press; Pacific Grove, CA 1983; 129-184.
159. Weil Z.M., Hotchkiss A.K., Gatien M.L. et al. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Research Bulletin 2006; 68: 425-429.
160. Zarate C.A., Du J., Quiroz J. et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann NY Acad Sci 2004; 1003: 273-291.
161. Zarate C.A. Jr., Singh J.B., Carlson P.J. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.